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Smoking and second-hand smoke (SHS) exposure have been recently linked to a higher risk of breast 
cancer in women. The aim of this work is to estimate the number of deaths and disability-adjusted 
life years (DALYs) from breast cancer attributable to these two risk factors in the European Union 
(EU-28) in 2017.  
The comparative risk assessment method was used. Data on prevalence of smoking and SHS exposure 
were extracted from the Eurobarometer surveys, relative risks from a recent meta-analysis, and data 
on mortality and DALYs from breast cancer were estimated from the Global Burden of Disease, 
Injuries and Risk Factors Study.  
In 2017, 82,239 DALYs and 3,354 deaths from breast cancer in the EU-28 could have been avoided 
by removing exposure to these two risk factors (smoking and SHS exposure). The proportion of 
DALYs from breast cancer lost respectively from smoking and SHS exposure was 2.6% and 1.0%, 
although geographically distributed with significant heterogeneity. 
These results represent the first estimates of breast cancer burden in women attributable to smoking 
and SHS exposure for the EU-28. It is important to increase awareness among women, health 
professionals and wider society of the association between smoking, SHS exposure and breast cancer, 
a relationship that is not widely recognised or discussed. 
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Novelty and Impact 
 
In 2017 in the European Union (EU-28) an estimated 82,239 years of life with disability and 3,354 




Among all disability-adjusted life years lost from breast cancer, 2.6% were due to smoking and 1.0% 
to second-hand smoke exposure. 
Although smoking (including SHS exposure) is not considered a major risk factor for breast cancer 
risk, the burden of disease from breast cancer attributable to smoking and SHS exposure is large in 
EU-28. 
The association between smoking and second-hand smoke exposure with breast cancer is poorly 






Tobacco smoke is the most ubiquitous, preventable human carcinogen and breast cancer is the 
leading cause of cancer among women, accounting for nearly one in four of all new cancer 
diagnoses worldwide in 2018, and about 15% of female cancer deaths. Among European women, 
breast cancer accounted for 523,000 new cases (28% of total cancers) in 2018, being also the 
leading cause of cancer-related deaths (138,000 deaths, 16% of total female cancer deaths), with the 
exception of Northern European countries, where it is now preceded by lung cancer1.  
Until 2004, reports published by expert groups, such as the International Agency for Research on 
Cancer (IARC), California Environmental Protection Agency (CalEPA), or the United States (US) 
Surgeon General, did not report any association between smoking and breast cancer. The 1986 
IARC monograph even indicated that smoking reduced breast cancer risk2.  
The 2005 CalEPA Report for the first time concluded that there was a positive association between 
smoking and breast cancer risk3, followed a few years later by a report by a group of Canadian 
experts4, and then by the 2012 monograph of the IARC, which for the first time, mentioned a causal 
relationship5. Also, the 2014 US Surgeon General reported an increased risk of breast cancer in 
smokers, particularly in post-menopausal women6. 
Regarding second-hand smoke (SHS) exposure, both the 2005 CalEPA Report and the Canadian 
study reported a relationship consistent with causality between SHS exposure and occurrence of 
breast cancer, particularly in women before menopause, whereas the 2014 US Surgeon General 
reported a possible association in non-smoking pre-menopausal women3-4,6. 
The 2015 meta-analysis of all published studies on this research topic reported significant 9% and 
20% increases in breast cancer risk respectively in smoking women and among non-smoking 
women exposed to SHS, surprisingly. However, high heterogeneity was observed among studies, 




Several theories have been put forward to explain why SHS exposure could have a similar or 
stronger effect on breast cancer than active smoking, and the debate is ongoing. According to one 
theory, smoking has an association with breast cancer weaker than expected due to the role of being 
both an anti-estrogenic protective factor and a risk factor for breast cancer2. According to others, 
SHS exposure has a predominant effect in pre-menopausal cancers, a hypothesis strongly supported 
by a Japanese cohort study that found a three times higher risk of developing breast cancer among 
SHS exposed women in pre-menopausal age, but not in post-menopausal age8.  
Overall, smoking prevalence in European Union (EU-28) has shown a slight decrease in recent 
years, yet with heterogeneous trends among countries, and, since the widespread implementation of 
smoking bans, important reductions in SHS exposure in EU-28 have been observed 9.  
It is important to highlight the impact that both smoking and SHS exposure have on women's health 
and to quantify the numbers of deaths and disability-adjusted life years (DALYs) lost that could be 
avoided.  The aim of this work, conducted within the TackSHS project, is to estimate the number of 
deaths and DALYs from breast cancer attributable to smoking and SHS exposure in the EU-28 in 
2017 10. 
 
Material and methods 
The burden from breast cancer attributable to smoking and SHS exposure was obtained using the 
comparative risk assessment method 11. Briefly, the smoking and SHS attributable fraction (AF) for 










where RR is the relative risk for exposed to smoking or SHS compared to non-exposed.  


















where CLC and NLC are the age-specific lung cancer mortality rate respectively for the all country 
under study and for never smokers only, and *LCS  and 
*
LCN  are lung cancer mortality rates for 
smokers and never-smokers, respectively, in a reference population. The SIR represents the 
accumulated risk from smoking, using lung cancer mortality excess as a biological marker for 
accumulated smoking hazards. Since the effect of smoking on breast cancer depend on the smoking 
exposure history, such as age of starting smoking and number of cigarettes smoked per day, the SIR 
is usually preferred to the smoking prevalence alone that is an insufficient indicator of accumulated 
risk from smoking 12.  
In the estimation of the AF from SHS, p is the 10-years lagged age and country-specific prevalence 
of SHS exposure. A 10-year lag between SHS exposure and breast cancer death/occurrence was 
assumed in computing the AF, due to an expected long latency, as for active smoking11. 
The number of breast cancer deaths/DALYs attributable to smoking was then obtained by 
multiplying the age- and country-specific number of breast cancer deaths/DALYs by the 
corresponding attributable fractions, and the burden attributable to SHS exposure was estimated 
among non-smoking women, because the impact of smoking could mask the effect due to SHS11.  
The Relative Risks (RR) for smoking women compared to non-smokers was 1.10 (95% confidence 
interval [95%CI]:1.09-1.12), and the RR for women exposed to SHS compared to non-exposed was 
1.07 (95% CI:1.02-1.13)7. The sources of data used in the analysis are reported in Table 1.  
For each estimate of deaths and DALYs attributable to smoking and SHS exposure, an uncertainty 
interval (UI) was obtained with a Monte Carlo procedure11.  
A sensitivity analysis was carried out by using RR estimated pooling all prospective and 
retrospective studies, even if highly heterogeneous (RR for smoking: 1.09 (95% CI:1.06-1.12); RR 
for SHS exposure 1.20 (95% CI:1.07-1.33)) 7. Moreover, an analysis estimating the burden form 
smoking by using the 10-years lagged prevalence of smoking instead of the SIR in the AF 




In the EU-28 in 2017, the number of DALYs from breast cancer attributable to smoking and SHS 
exposure was estimated as of 50,610 (UI:42,506-61,471) and 10,123 (UI:6,793-14,377) 
respectively, and the number of deaths was 2,340 (UI:1,953-2,886) and 379 (UI:239-601). The 
proportion of breast cancer DALYs attributable to smoking and SHS exposure on the 2,254,992 
total DALYs from breast cancer were respectively 2.2% and 0.4% (Figure 1), whereas the 
proportion of deaths were 2.3% and 0.4%, respectively (101,935 total deaths from breast cancer).  
In terms of both DALYs and deaths, the highest burden due to both risk factors (smoking and SHS 
exposure) was estimated in Denmark, Malta, Croatia, Hungary and in the United Kingdom, with a 
proportion on the total breast cancer DALYs and deaths higher than 4% and 5%, respectively. The 
lowest burden was estimated in Cyprus, Lithuania, Latvia, Italy and Estonia with a proportion less 
than 1.5%.The proportion of DALYs and deaths from breast cancer attributable to smoking was 
higher than that due to SHS exposure for all EU-28 countries (Figure 1).  
In the sensitivity analysis using meta-analytical RR of breast cancer with a high heterogeneity, the 
rank of the countries by the burden from both smoking and SHS exposure was similar to the main 
results, but for some countries, i.e. Cyprus, Lithuania, Italy, Romania, Slovenia, Spain, and 
Bulgaria, the proportion of DALYs from breast cancer attributable to SHS exposure was higher 
than that due to smoking.Using the 10-year lagged smoking prevalence instead of the SIR in the AF 
estimation produced an estimate of 48,619 (UI:40,067-58,386) and 10,122 (UI:6,791-14,365) 
DALYs from breast cancer attributable respectively to smoking and SHS exposure, and 1,752 
(UI:1,387-2,222) and 378 (UI:239-603) deaths. 
 
Discussion 
In 2017, 50,610 (2340) and 10,123 (379) years of life lived with disability (deaths) could have been 
avoided, by removing respectively smoking and SHS exposure in the home, in the EU-28, and in all 
countries the burden from smoking was larger than from SHS exposure. The burden from these two 
risk factors varied considerable across EU-28 countries, with a geographic gradient. On the one 
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hand, the North-Western countries showed the largest proportion of breast cancer DALYs 
attributable to smoking. In these countries, as well as in Austria, Czech Republic, Finland, Hungary, 
Ireland, The Netherlands, Poland, Slovenia, and Sweden, lung cancer was the leading cause of 
cancer deaths among women, as a consequence of earlier widespread tobacco consumption among 
women1. Moreover, in most of these countries SHS exposure prevalence is lower with consequently 
lower burden from SHS.  
On the other hand, South-Eastern EU-28 countries showed comparatively greater exposure to SHS 
and thus larger proportions of breast cancer DALYs attributable to SHS exposure, with over 0.7% 
in Greece, Bulgaria, and Hungary. By considering a higher risk from SHS exposure, even if 
estimated with a large heterogeneity, the same countries showed proportions of breast cancer 
DALYs attributable to SHS exposure over 1.6%. In the South-Eastern countries the burden from 
breast cancer due to smoking was lower than that due to SHS exposure as a consequence of the 
lower smoking prevalence than that recorded among women of North-Western countries.  
Differently from other studies, the analyses on SHS exposure were carried out by considering 
household exposure only in order to explore the burden unrelated with the current legislation. 
The SIR approach in the estimation of the burden attributable to smoking is usually the preferred 
method because it considers the accumulated risk from smoking, but also because uses lung cancer 
mortality data, which are easily available for all countries 16. Using a lagged prevalence of smoking 
in order to take into account for the time period between exposure and cancer occurrence, gives 
smaller attributable fractions than SIR-based estimates among females 17, and this is confirmed in 
our sensitivity analysis. 
The GBD framework provides a comprehensive assessment of risk factor exposure and attributable 
burden of disease, estimated for 2017 in EU-28 a PAF to smoking of 6.8% and 5.7% for DALYs 
and deaths, respectively 13. Another study on the burden from smoking on cancers that analysed five 
European cohorts reported a proportion of attributable DALYs of 4.7%18, whereas a study carried 
out in Norway estimated a PAF to smoking of 11.9% 19. Similar values were estimated in the 
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present study for northern countries, such as Denmark (5.9%) and Great Britain (4.8%). Possible 
explanations of such differences could be in the distributions of risk factors and RR in the 
populations under study.  
The association between SHS exposure and breast cancer needs further evidence. Within the last ten 
years only four groups investigated the burden from breast cancer due to SHS exposure. The results 
of these studies produced estimates of attributable fractions between 1.07% and 1.68% that are 
higher in comparison to our estimates20. The PAF to SHS exposure estimated from GBD for the 
EU-28 are 1.7% and 1.4% for DALYs and deaths, respectively, whereas the Norwegian study 
estimated a PAF of 3.2% 13. The main differences in these results could be explained by the 
different definition for SHS exposure, that in our case refers to household exposure only. 
This study has some limitations. In the SIR approach, we are using the lung cancer mortality as an 
indicator of smoking exposure history; however, the relationship of active smoking to breast cancer 
may depend also from other measures, such as years of smoking before first childbirth20. Moreover, 
in the SIR estimation, as lung cancer death rates in non-smokers of the population under study we 
used, for all countries, a pooled estimate from never smokers of European Descent extracted from 
the Thun et al. (2008) study 14 since no rates specific for each Europe Union country was available. 
We used an estimate of RR of breast cancer for overall SHS exposure, that are extracted from 
different studies exploring the effect of SHS exposure defined in several different ways, i.e. spousal 
exposure, household exposure, workplace exposure. This could generate biased conservative 
estimates since the analyses are carried out by considering household exposure only. Moreover, we 
assumed the same RR for all ages since there were no robust meta-analytical RR estimates by age in 
the literature, even if there is evidence that pre-menopausal and post-menopausal breast cancer risks 
for active and SHS risks may differ8.   
In conclusion, to our knowledge, this is the first estimate on the burden from breast cancer 
attributable to smoking and SHS exposure in the EU-28. Although smoking (including SHS 
exposure) is not considered a major risk factor for breast cancer risk, the burden of disease from 
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breast cancer attributable to smoking and SHS exposure is large in EU-28, and, given that 
awareness of both smoking and SHS exposure as risk factors for breast cancer is still low among the 
population, it is important to spread this link among the public and all stakeholders. Smoking and 
exposure to SHS are modifiable risk factors, and therefore important objects of primary prevention 
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Table 1 – Sources of data used for the analyses. SHS: second-hand smoke. 
Variable Source 
Country and age-specific prevalence of SHS exposure at home in non 
smoking women in 2006 for the estimation of attributable fractions 
(defined as being ever exposed in the home daily) 
Eurobarometer surveys9 
Country and age-specific prevalence smoking women in 2017 for the 
estimation of non-smoking women 
Eurobarometer surveys9 
Relative risk of breast cancer for exposed to SHS compared to not exposed 
and for smokers compared to non smokers 
Meta-analysis 7 
Country and age-specific lung cancer mortality rate in 2017 (CLC) for SIR 
estimation 
Global Health Data Exchange of the 
Global Burden of Disease study 13 
Country and age-specific lung cancer mortality rate for never smokers 
only (NLC) 
Pooled estimate among white lifelong 
never smokers of European Descent 14 






Estimate from Cancer Prevention 2 
study 15 
Country-specific estimates of mortality and DALYs from breast cancer Global Health Data Exchange of the 




Table 2 – Prevalence of household second-hand smoke exposure in 2006 (SHS), smoking 
prevalence in 2006 (smoking), Smoking Impact Ratios (SIR), disability adjusted life years from 
breast cancer in 2017 (DALYs) and deaths from breast cancer in 2017 (deaths) for women aged 15-
80+ years with 95% confidence intervals (CI) or uncertainty intervals (UI).  
country 
SHS  
% (95% CI) 
Smoking 
% (95% CI) 
SIR  
% (95% UI) 
DALYs 
% (95% UI) 
Deaths 
% (95% UI) 
Austria 
10.3 
(6.5,14.1) 24.3 (19,29.5) 22.7 (15.7,43.6) 35328 (41237,29942) 1688 (1462,1938) 
Belgium 4.5 (2.2,6.8) 21.9 (17.4,26.5) 24.5 (16.8,46.8) 52913 (62554,44121) 2450 (2088,2831) 
Bulgaria 15 (10.4,19.5) 29.6 (23.9,35.3) 11.2 (7.1,28.2) 34462 (41761,28086) 1356 (1120,1624) 
Cyprus 9.3 (3,15.6) 16.1 (10.9,21.2) 5.9 (3.9,19.2) 4645 (5972,3504) 169 (129,212) 
Czech Republic 6.2 (3.2,9.2) 23.1 (18.5,27.8) 18.3 (12.9,36.9) 37669 (44246,31704) 1708 (1465,1974) 
Germany 6.6 (4,9.2) 25.3 (22.3,28.3) 17.3 (11.8,36) 431661 (529364,347861) 20000 (16469,24073) 
Denmark 4.2 (2,6.3) 28.8 (21.8,35.9) 44.7 (31.9,73.4) 27614 (32734,23135) 1294 (1106,1505) 
Estonia 3.5 (0.8,6.1) 24 (9.9,38.1) 9.6 (6.6,24.4) 4996 (6370,3831) 219 (172,274) 
Spain 
10.8 
(6.7,14.8) 28.3 (25.9,30.7) 13.1 (9.3,29.3) 151940 (178790,128086) 6749 (5815,7784) 
Finland 2.4 (0.6,4.1) 22.5 (16,29) 20.7 (13.5,42.3) 21210 (25316,17655) 917 (777,1073) 
France 7.9 (4.6,11.2) 27 (24.8,29.1) 24.8 (17,47) 282360 (334740,235115) 13321 (11376,15442) 
United 
Kingdom 4.2 (1.9,6.5) 31.9 (28.4,35.4) 34.4 (24.5,59.1) 307453 (324528,291743) 13757 (13356,14190) 
Greece 
12.1 
(7.8,16.5) 36.7 (31.4,42) 16.2 (10.8,34.9) 48772 (57738,40731) 2286 (1953,2652) 
Croatia 
11.4 
(7.1,15.6) 25.1 (17.9,32.3) 44.2 (30.1,68) 19720 (23238,16635) 951 (815,1107) 
Hungary 
14.9 
(9.9,19.9) 29.3 (24.3,34.3) 30.3 (21.6,54.4) 45970 (53912,38886) 2045 (1757,2365) 
Ireland 8.6 (5.2,11.9) 29.4 (21,37.9) 13.8 (9.4,30.9) 18578 (22549,15134) 746 (617,892) 
Italy 7.2 (3.4,10.9) 23.8 (21.8,25.7) 6.7 (4.4,20.4) 271655 (318234,228855) 12769 (10970,14667) 
Lithuania 4.6 (1.5,7.8) 20.2 (12.6,27.8) 5.7 (3.6,19.1) 12627 (15128,10414) 524 (439,620) 
Luxembourg 2.6 (0,5.5) 23.4 (0.8,45.9) 24.4 (16.8,46.7) 2415 (3046,1862) 104 (82,128) 
Latvia 8.9 (4.8,13) 21.3 (10.4,32.2) 7.2 (4.8,21.2) 9098 (11498,7104) 393 (312,491) 
Malta 3.2 (0,6.9) 21.6 (-2.1,45.4) 41.3 (28.9,69.8) 2328 (2815,1887) 100 (83,120) 
Netherlands 5.6 (2.9,8.3) 27.5 (23.5,31.5) 28.3 (19.8,51.4) 88115 (103121,74613) 3859 (3342,4430) 
Poland 
13.8 
(9.4,18.2) 29.8 (27.2,32.4) 7.5 (4.6,22.3) 148977 (176781,123973) 6189 (5224,7244) 
Portugal 4.5 (1.7,7.4) 13.9 (10,17.9) 13.3 (8.7,30.6) 43016 (51561,35325) 1927 (1618,2268) 
Romania 
11.1 
(7.1,15.1) 19.9 (16.9,23) 12.2 (8.2,28.6) 82129 (95804,69693) 3345 (2867,3871) 
Sweden 4 (2,5.9) 21.8 (16.9,26.8) 18.4 (12.5,37.6) 39547 (45131,34523) 1787 (1590,1999) 
Slovenia 
11.1 
(7.5,14.8) 21.2 (11.1,31.3) 10.9 (6.8,27.4) 8034 (9720,6567) 384 (322,455) 
Slovakia 5.6 (2.7,8.4) 18.8 (12.8,24.9) 22 (15.9,41.7) 21760 (27502,16189) 898 (651,1118) 








Figure 1 – Proportion of a) DALYs and b) deaths from breast cancer attributable to smoking and second-hand 
smoke exposure in 2017 in the European Union countries.  
 a) b) 
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